T. Opgenorth

发表

Azole endothelin antagonists. 2. Structure-activity studies.

J. R. Wu-wong, W. Chiou, T. V. Geldern, 1996, Journal of medicinal chemistry.

Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.

S. Magnuson, K. Marsh, J. R. Wu-wong, 1996, The Journal of pharmacology and experimental therapeutics.

The effects of diminishing albumin binding to some Endothelin receptor antagonists.

K. Marsh, J. R. Wu-wong, W. Chiou, 1998, Life sciences.

Selective antagonism of the hepatic glucocorticoid receptor reduces hepatic glucose production.

D. Edgerton, A. Cherrington, D. Beno, 2006, Metabolism: clinical and experimental.

Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors.

C. Wegner, B. Cox, G. Reinhart, 2002, American journal of physiology. Heart and circulatory physiology.

The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.

S. Oparil, Yiu-fai Chen, J. Wessale, 1997, Journal of cardiovascular pharmacology.

A familial risk of chronic renal failure among blacks on dialysis?

C. Grim, T. Opgenorth, R. Ferguson, 1988, Journal of clinical epidemiology.

Role of prostaglandins in the cortical distribution of renal blood flow following reductions in renal perfusion pressure.

M. Fiksen-Olsen, J. C. Romero, T. Opgenorth, 1987, Prostaglandins.

Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies.

H. Lepor, E. Shapiro, T. Opgenorth, 1993, The Journal of urology.

Atrial natriuretic peptide elevation in congestive heart failure in the human.

G. Reeder, P. Kao, J. Granger, 1986, Science.

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade.

J. Nelson, L. Chung, J. R. Wu-wong, 1999, Urology.

Beneficial effect of the ANF analog A68828 on recovery from ischemic acute renal failure.

D. Pollock, T. Opgenorth, 1992, Renal failure.

An Essential Myosin Light Chain Peptide Induces Supramaximal Stimulation of Cardiac Myofibrillar ATPase Activity*

R. Solaro, J. R. Wu-wong, T. Opgenorth, 1996, The Journal of Biological Chemistry.

Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance.

P. Jacobson, D. Wilcox, B. Zinker, 2007, Metabolism: clinical and experimental.

Perioperative plasma endothelin-1 and Big endothelin-1 concentrations in elderly patients undergoing major surgical procedures.

L. Fleisher, J. Nelson, S. Frank, 1999, Anesthesia and analgesia.

Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation.

D. Pollock, T. Opgenorth, 1993, The American journal of physiology.

Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes

L. Öhman, D. Edgerton, A. Cherrington, 2005, Journal of Pharmacology and Experimental Therapeutics.

Metabolic responses with endothelin antagonism in a model of insulin resistance.

J. Wessale, B. Zinker, T. Opgenorth, 2005, Metabolism: clinical and experimental.

Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.

M. Takaoka, Y. Matsumura, T. Opgenorth, 1999, Hypertension.

Characterization of endothelin converting enzyme in rat lung.

J. R. Wu-wong, G. Budzik, T. Opgenorth, 1990, Biochemical and biophysical research communications.

The epidemiology of end-state renal disease: the six-year South-Central Los Angeles experience, 1980-85.

C. Grim, T. Opgenorth, R. Ferguson, 1987, American journal of public health.

The Roles of Endothelins in Proliferation, Apoptosis, and Angiogenesis

J. R. Wu-wong, T. Opgenorth, 2001 .

Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs.

C. Wegner, B. Dayton, J. Wessale, 1997, Journal of cardiovascular pharmacology.

Endothelin attenuates apoptosis in human smooth muscle cells.

J. R. Wu-wong, W. Chiou, T. Opgenorth, 1997, The Biochemical journal.

Endothelin-1-evoked arachidonic acid release: a Ca(2+)-dependent pathway.

J. R. Wu-wong, B. Dayton, T. Opgenorth, 1996, The American journal of physiology.

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II.

A. Haramati, S. Mulroney, Z. Abassi, 1997, Circulation.

[14] Characterization of endothelin-converting enzymes

S. Kimura, J. R. Wu-wong, T. Opgenorth, 1995 .

Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.

D. Pollock, J. Polakowski, T. Opgenorth, 1993, The Journal of pharmacology and experimental therapeutics.

Specific Inhibition of Glycosylation by Tunicamycin Affects Endothelin Receptors in Cultured Swiss 3T3 Fibroblasts

J. R. Wu-wong, T. Opgenorth, 1993 .

Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level.

J. R. Wu-wong, J. Wessale, R. Padley, 2000, Journal of cardiovascular pharmacology.

Endothelins in canine genitourinary tissues.

H. Lepor, E. Shapiro, T. Opgenorth, 1997, The Journal of urology.

[3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors.

D. Kerkman, A. Tasker, J. Debernardis, 1994, European journal of pharmacology.

Exaggerated Vascular and Renal Pathology in Endothelin-B Receptor–Deficient Rats With Deoxycorticosterone Acetate–Salt Hypertension

M. Yanagisawa, C. Gariepy, M. Takaoka, 2000, Circulation.

Elevated levels of atrial natriuretic peptide during aldosterone escape.

J. Granger, M. Joyce, J. Burnett, 1987, The American journal of physiology.

Renal effects of ANP without changes in glomerular filtration rate and blood pressure.

M. Fiksen-Olsen, J. Granger, J. Burnett, 1986, The American journal of physiology.

Atrial natriuretic peptides in the treatment of acute renal failure.

D. Pollock, T. Opgenorth, 1993, Renal failure.

ETA receptor‐mediated responses to endothelin‐1 and big endothelin‐1 in the rat kidney

D. Pollock, T. Opgenorth, 1994, British journal of pharmacology.

Characterisation of functional endothelin receptors in the canine isolated perfused spleen.

R. Zatz, G. De Nucci, D. Grassi-Kassisse, 1995, European journal of pharmacology.

Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.

K. Marsh, J. R. Wu-wong, B. Dayton, 2002, Clinical science.

Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade.

R. Fryer, B. Cox, G. Reinhart, 2006, American journal of physiology. Heart and circulatory physiology.

2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.

A. Tasker, K. Marsh, J. R. Wu-wong, 1996, Journal of medicinal chemistry.

Endothelin‐converting enzymes

J. R. Wu-wong, K. Shiosaki, T. Opgenorth, 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.

M. Jarvis, J. J. Lynch, B. Dayton, 2000, European journal of pharmacology.

Delivery of RNAi reagents in murine models of obesity and diabetes

E. Bush, P. Jung, C. Rondinone, 2006, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin.

J. Granger, A. Alberola, T. Opgenorth, 1995, The American journal of physiology.

Direct determination of endothelin receptor antagonist levels in plasma using a scintillation proximity assay.

J. R. Wu-wong, B. Dayton, W. Chiou, 2000, Life sciences.

Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.

K. Marsh, J. Wu-Wong, B. Dayton, 1999, European journal of pharmacology.

Truncated atrial natriuretic factor analogs retain full agonist activity.

D. Pollock, G. Budzik, W. Holleman, 1991, Canadian journal of physiology and pharmacology.

Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.

A. Tasker, J. R. Wu-wong, M. Winn, 2002, Clinical science.

'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects.

J. R. Wu-wong, W. Chiou, J. Wessale, 2000, Journal of cardiovascular pharmacology.

Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in rats.

M. Takaoka, J. Wessale, Y. Matsumura, 2000, Japanese journal of pharmacology.

Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity.

A. Tasker, K. Marsh, C. Hutchins, 1999, Bioorganic & medicinal chemistry.

Effects of human plasma proteins on endothelin binding and function.

J. R. Wu-wong, D. Dixon, T. Opgenorth, 1998, Journal of cardiovascular pharmacology.

Characterization of endothelin receptors in isolated, perfused human spleen.

G. De Nucci, I. Boin, E. Antunes, 1998, Journal of cardiovascular pharmacology.

Endothelin and isoproterenol counter-regulate cAMP and mitogen-activated protein kinases.

J. R. Wu-wong, T. Opgenorth, 1998, Journal of cardiovascular pharmacology.

Dissociation characteristics of endothelin receptor agonists and antagonists in cloned human type-B endothelin receptor.

S. Magnuson, J. R. Wu-wong, W. Chiou, 1997, Endothelium : journal of endothelial cell research.

Endothelins and endothelin receptor antagonists: binding to plasma proteins.

J. R. Wu-wong, M. Winn, W. Chiou, 1996, Life sciences.

Endothelin receptor agonists and antagonists exhibit different dissociation characteristics.

S. Magnuson, J. R. Wu-wong, W. Chiou, 1994, Biochimica et biophysica acta.

Localization of endothelin receptors in the human prostate.

H. Lepor, E. Shapiro, S. Kobayashi, 1994, The Journal of urology.

Endothelin receptor antagonists exhibit diminishing potency following incubation with agonist.

J. R. Wu-wong, W. Chiou, T. Opgenorth, 1994, Life sciences.

In vivo characterization of a phosphoramidon-sensitive endothelin-converting enzyme in the rat.

N. Burres, D. Pollock, T. Opgenorth, 1993, European journal of pharmacology.

Surgery and Plasma Infusion Increase Circulating Immunoreactive Endothelin in the Anesthetized Rat

D. Pollock, T. Opgenorth, B. Divish, 1993 .

Effect of cell density on endothelin release from endothelial cells and phosphoramidon dependent inhibition.

G. Budzik, R. Zaragoza, T. Opgenorth, 1992, Biochemical pharmacology.

Atrial natriuretic factor and endothelin interactions in control of vascular tone.

T. Opgenorth, E. Novosad, 1990, European journal of pharmacology.

The renal action of atrial natriuretic peptide during control of glomerular filtration.

J. Granger, J. Burnett, T. Opgenorth, 1986, Kidney international.

HPLC and PDMS analysis of cleavage products aid in the design of small, stable ANP analogues.

S. Davidsen, W. Holleman, A. Buko, 2009, International journal of peptide and protein research.

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.

K. Marsh, M. Winn, D. Dixon, 1997, Journal of medicinal chemistry.

Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.

P. Mulder, V. Richard, G. Derumeaux, 2000, Circulation.

Atrial peptides induce mast cell histamine release

M. R. Holst, S. Davidsen, G. Budzik, 1990, Peptides.

Increased susceptibility to deoxycorticosterone acetate-salt-induced hypertension in endothelin-B-receptor-deficient rats.

M. Yanagisawa, C. Gariepy, M. Takaoka, 2000, Journal of cardiovascular pharmacology.

Endothelin and ET(A) receptors in long-term arterial pressure homeostasis in conscious nonhuman primates.

C. Wegner, B. Cox, G. Reinhart, 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1.

D. Pollock, T. Opgenorth, David M. Pollock, 1991, The American journal of physiology.

Endothelin receptor in human astrocytoma U373MG cells: binding, dissociation, receptor internalization.

S. Magnuson, J. R. Wu-wong, W. Chiou, 1995, The Journal of pharmacology and experimental therapeutics.

Role of endothelin ET(A) receptors in the hypertension produced by 4-day L-nitroarginine methyl ester and cyclosporine treatment.

J. Pollock, D. Pollock, J. Polakowski, 1998, European journal of pharmacology.

Effects of atrial natriuretic peptide on renin secretion in nonfiltering kidney.

J. Granger, J. Burnett, T. Opgenorth, 1986, The American journal of physiology.

Atrial natriuretic peptide antagonists: biological evaluation and structural correlations.

Y. Kiso, G. Budzik, W. Holleman, 1990, Molecular pharmacology.

Atrial natriuretic peptide (ANP) does not inhibit the basal vascular tone present in the in situ blood-perfused dog gracilis muscle.

R. Klabunde, T. Opgenorth, E. Novosad, 1990, Life sciences.

Characterization of antihypertensive activity of ABBOTT-81988, a nonpeptide angiotensin II antagonist in the renal hypertensive rat.

D. Kerkman, J. Debernardis, M. Winn, 1994, The Journal of pharmacology and experimental therapeutics.

5-Membered ring heterocyclic carboxylic acids as angiotensin II antagonists

D. Kerkman, S. Rosenberg, M. Winn, 1994 .

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.

K. Marsh, M. Winn, W. Chiou, 2001, Journal of medicinal chemistry.

PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice

J. Waring, R. Ulrich, S. Crosby, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Role of the Endothelin System in Secondary Pulmonary Hypertension Related to Air Embolism: Lessons Learned from Testing Four Classes of Endothelin Blockers in a Rat Model

M. Verreault, J. Wessale, B. Battistini, 2004, Journal of cardiovascular pharmacology.

The Contribution of the Bladder to Calcium Oxalate Crystal Growth Inhibition in Voided Urine

Lynwood H. Smith, J. C. Romero, T. Opgenorth, 1985 .

Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition.

D. Pollock, J. Polakowski, T. Opgenorth, 1993, Hypertension.

Endothelin receptor antagonism.

T. Opgenorth, 1995, Advances in pharmacology.

Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.

A. Tasker, K. Marsh, B. Dayton, 1997, Journal of medicinal chemistry.

A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study.

C. Sotak, M. Fisher, R. Carano, 1998, Stroke.

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.

S. Magnuson, J. Nelson, J. Simons, 1996, Cancer research.

Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer.

J. Brooks, S. Magnuson, J. Nelson, 1997, Cancer research.

Chronic oral endothelin type A receptor antagonism in experimental heart failure.

M. Redfield, A. Luchner, E. Williamson, 1998, Hypertension.

Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model.

R. Schwartz, D. Holmes, A. Lerman, 1998, Circulation.

Dissociation Characteristics of Endothelin ETA Receptor Agonists and Antagonists

J. R. Wu-wong, W. Chiou, D. Dixon, 1995, Journal of cardiovascular pharmacology.

Effects of synthetic atrial natriuretic factor on renal function and renin release.

J. Granger, J. Burnett, J C Burnett, 1984, The American journal of physiology.

Atrial natriuretic peptide and glomerular hyperfiltration during onset of spontaneous diabetes mellitus.

R. Vari, T. Opgenorth, T. V. von Geldern, 1994, American Journal of Physiology.

Endothelin ETA receptor antagonist reduces myocardial infarction induced by coronary artery occlusion and reperfusion in the rat.

R. Warner, T. Opgenorth, A. Adler, 1994, Pharmacology.

Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.

A. Tasker, K. Marsh, M. Winn, 1999, Journal of Medicinal Chemistry.

Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics.

J. Wu-Wong, W. Chiou, J R Wu-Wong, 1997, The Journal of pharmacology and experimental therapeutics.

Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.

K. Marsh, J. R. Wu-wong, B. Dayton, 1996, Journal of medicinal chemistry.

Design, synthesis, and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain.

K. Marsh, M. Winn, W. Chiou, 1999, Journal of medicinal chemistry.

Endothelin receptor in benign prostatic hyperplastic cells. Binding and functional studies.

S. Magnuson, S. Ng, J. R. Wu-wong, 1997, Receptors & signal transduction.

Binding and functional properties of endothelin receptor subtypes in the human prostate.

H. Lepor, E. Shapiro, S. Kobayashi, 1994, Molecular pharmacology.

Effects of a selective endothelin A receptor antagonist, ABT-627, in healthy normotensive anaesthetized rats developing acute pulmonary air embolism.

A. Jeng, J. R. Wu-wong, J. Wessale, 2002, Clinical science.

Effect of ABT‐627 (A‐147627), a potent selective ETA receptor antagonist, on the cardiopulmonary profile of newborn lambs with surgically‐induced diaphragmatic hernia

J. Wessale, B. Battistini, T. Opgenorth, 2001, British journal of pharmacology.

Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy.

C. Wegner, D. Pollock, D M Pollock, 1997, Renal failure.

Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition.

T. Rabelink, A. Verhagen, J. Joles, 1998, Journal of the American Society of Nephrology : JASN.

Plasma endothelin-1 levels neither increase nor correlate with neurological scores, stroke risk factors, or outcome in patients with ischemic stroke.

M. Kaste, L. Soinne, T. Tatlisumak, 2000, Stroke.

Long‐Term Hypotensive and Renal Effects of Atrial Natriuretic Peptide

J. Granger, J. Burnett, T. Opgenorth, 1986, Hypertension.

Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.

C. Hutchins, J. R. Wu-wong, W. Chiou, 1996, Journal of medicinal chemistry.

Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme.

D. Pollock, G. Sullivan, K. Shiosaki, 1992, Biochemical and biophysical research communications.

Effect of the Endothelin ETA Receptor Antagonist, BQ-123, on Pressor Responses to Endothelin Family Peptides

D. Pollock, J. Polakowski, T. Opgenorth, 1993 .

Endothelin receptors in human smooth muscle cells: antagonist potency differs on agonist-evoked responses.

J. R. Wu-wong, W. Chiou, T. Opgenorth, 1994, The American journal of physiology.

Beneficial effect of the atrial natriuretic factor analog A68828 in postischemic acute renal failure.

D. Pollock, T. Opgenorth, David M. Pollock, 1990, The Journal of pharmacology and experimental therapeutics.

Chronic pathophysiologic circulating endothelin levels produce hypertension in conscious dogs.

J. Granger, A. Alberola, T. Opgenorth, 1993, Journal of cardiovascular pharmacology.

Temporary Middle Cerebral Artery Occlusion : A Diffusion and Perfusion MRI Study A Novel Endothelin Antagonist , A-127722 , Attenuates Ischemic Lesion Size in Rats With

C. Sotak, M. Fisher, R. Carano, 1998 .

Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II.

R. Zimmerman, T. Schwab, J. Burnett, 1988, The American journal of physiology.